1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-16915
    RPR-260243 668463-35-2 ≥99.0%
    RPR-260243, a potent activator of human ether-a-go-go-related gene (hERG), slows deactivation and attenuates inactivation of hERG1 channels. RPR260243-modified HERG currents are inhibited by Dofetilide (IC50=58 nM). RPR260243 displays no activator-like effects on other voltage-dependent ion channels, including the closely related ERG3 K+ channel. RPR-260243 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    RPR-260243
  • HY-16991
    Terutroban 165538-40-9
    Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties.
    Terutroban
  • HY-100897
    Sulodexide 57821-29-1
    Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease.
    Sulodexide
  • HY-109002
    Apararenone 945966-46-1 99.09%
    Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.
    Apararenone
  • HY-120274
    Balcinrenone 1850385-64-6 99.96%
    Balcinrenone (AZD9977) is a potent, selective, and orally active mineralocorticoid receptor (MR) modulator. Balcinrenone is used for heart failure, and chronic kidney disease research.
    Balcinrenone
  • HY-P99505
    Ziltivekimab 2226654-05-1 99.75%
    Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis.
    Ziltivekimab
  • HY-P99810
    Quisovalimab 2427667-03-4
    Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies.
    Quisovalimab
  • HY-103265D
    ARL67156 triethylamine ≥98.0%
    ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma.
    ARL67156 triethylamine
  • HY-14165
    Veliflapon 128253-31-6 ≥99.0%
    Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.
    Veliflapon
  • HY-14739
    Choline Fenofibrate 856676-23-8 99.86%
    Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect.
    Choline Fenofibrate
  • HY-16126
    Carboxyamidotriazole 99519-84-3 ≥99.0%
    Carboxyamidotriazole (L-651582) is an orally active cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole inhibits NF-κB, MAPK activation and NO production. Carboxyamidotriazole has anti-angiogenic and anti-inflammatory activities. Carboxyamidotriazole has anticancer activity against liver cancer, lung cancer and leukemia.
    Carboxyamidotriazole
  • HY-16953
    JNJ 303 878489-28-2 99.60%
    JNJ-303 is a specific delayed rectifier Kv blocker. JNJ 303 can potent block IKs with an IC50 value of 64 nM. JNJ-303 can be used for the research of diabetes, obesity and central nervous system.
    JNJ 303
  • HY-18775
    N6-(4-Hydroxybenzyl)adenosine 110505-75-4 ≥98.0%
    N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.
    N6-(4-Hydroxybenzyl)adenosine
  • HY-19986
    AAL993 269390-77-4 99.50%
    IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, and VEGFR3/Flt-4, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties.
    AAL993
  • HY-33351
    Eugenin 480-34-2 99.02%
    Eugenin is a chromone that can be isolated from Formosan Peucedanum japonicum and has an effective antiplatelet aggregation effect. In addition, Eugenin has certain cytotoxicity against tumor cells.
    Eugenin
  • HY-77521
    Dabigatran ethyl ester hydrochloride 211914-50-0
    Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and a thrombin inhibitor.
    Dabigatran ethyl ester hydrochloride
  • HY-B0093
    Benazepril 86541-75-5
    Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy.
    Benazepril
  • HY-B0310
    Nizatidine 76963-41-2 99.68%
    Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models.
    Nizatidine
  • HY-B0325
    Phenindione 83-12-5 98.21%
    Phenindione is an anticoagulant and can act as a vitamin K antagonist.
    Phenindione
  • HY-B0924
    Anisindione 117-37-3 98.07%
    Anisindione is a synthetic anticoagulant. It inhibits the formation of active procoagulant factors II, VII, IX, and X.
    Anisindione
Cat. No. Product Name / Synonyms Application Reactivity